Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-16

Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma; study completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carfilzomib (carfilzomib)
  • DEXAMETHASONE (Dexamethasone)
  • Lenalidomide (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-16